ETF Holdings Breakdown of SRPT

News associated with SRPT

Mizuho Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price lowered by Mizuho from $85.00 to $40.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Mizuho’s price target indicates a potential upside of 92.59% from the company’s current price. A number of other […] - 2025-06-20 05:50:52

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 3% After Analyst Downgrade

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price was down 3% during trading on Wednesday after Mizuho lowered their price target on the stock from $85.00 to $40.00. Mizuho currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $20.51 and last traded at $20.92. Approximately 1,303,121 shares were […] - 2025-06-20 05:08:53

Robert W. Baird Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $30.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target decreased by stock analysts at Robert W. Baird from $60.00 to $30.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 44.44% from […] - 2025-06-19 08:02:54

Barclays Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective cut by investment analysts at Barclays from $89.00 to $29.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 39.62% from the stock’s current […] - 2025-06-19 05:42:49

Wells Fargo & Company Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $75.00

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target lowered by stock analysts at Wells Fargo & Company from $100.00 to $75.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside […] - 2025-06-19 05:42:47

Sarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors bought 10,954 call options on the company. This is an increase of 82% compared to the average volume of 6,025 call options. Sarepta Therapeutics Trading Down 3.7% Shares of SRPT stock opened at $20.77 on Thursday. The […] - 2025-06-19 05:10:47

Sarepta Therapeutics (NASDAQ:SRPT) Given New $25.00 Price Target at Deutsche Bank Aktiengesellschaft

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lowered by Deutsche Bank Aktiengesellschaft from $50.00 to $25.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a hold rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. Oppenheimer reduced their price target on shares […] - 2025-06-18 08:22:56

Bank of America Reiterates “Neutral” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at Bank of America in a research report issued on Monday, MarketBeat Ratings reports. They currently have a $28.00 target price on the biotechnology company’s stock, down from their previous target price of $76.00. Bank of America‘s target price […] - 2025-06-18 07:36:47

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $50.00 by Analysts at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target decreased by investment analysts at Needham & Company LLC from $125.00 to $50.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target would suggest a potential upside […] - 2025-06-18 05:50:54

Jefferies Financial Group Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target cut by investment analysts at Jefferies Financial Group from $125.00 to $54.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 150.46% […] - 2025-06-18 05:50:51

Cantor Fitzgerald Reaffirms Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Marketbeat Ratings reports. SRPT has been the subject of several other research reports. Wells Fargo & Company lowered their price objective on Sarepta Therapeutics from $115.00 to $100.00 and […] - 2025-06-18 05:50:50

Sarepta Therapeutics (NASDAQ:SRPT) Hits New 12-Month Low Following Analyst Downgrade

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) hit a new 52-week low on Monday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from $50.00 to $25.00. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock. Sarepta Therapeutics traded as low as $18.66 and last traded at $18.84, […] - 2025-06-18 05:12:44

Company News for Jun 17, 2025

Companies in The News Are: RNW, NOC, SRPT, AMD. - 2025-06-17 13:23:00

Focus Partners Wealth Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Focus Partners Wealth increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 30.0% during the 4th quarter, HoldingsChannel reports. The firm owned 2,275 shares of the biotechnology company’s stock after buying an additional 525 shares during the period. Focus Partners Wealth’s holdings in Sarepta Therapeutics were worth $277,000 at the end of […] - 2025-05-23 08:04:58

Cetera Investment Advisers Buys 463 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Cetera Investment Advisers grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 4.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 11,174 shares of the biotechnology company’s stock after purchasing an additional 463 shares during the quarter. Cetera Investment Advisers’ holdings in Sarepta Therapeutics were worth $1,359,000 as of its […] - 2025-05-22 08:03:00

Stifel Financial Corp Sells 27,138 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Stifel Financial Corp cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 72.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,069 shares of the biotechnology company’s stock after selling 27,138 shares during the quarter. Stifel Financial Corp’s […] - 2025-05-09 08:23:04

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $157.95 Consensus PT from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-three research firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has assigned a strong buy […] - 2025-05-09 07:07:04

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 19% Following Weak Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) was down 19% during mid-day trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $56.36 and last traded at $51.54. Approximately 2,597,711 shares traded hands during trading, an increase of 80% from the average daily volume of 1,442,184 shares. The […] - 2025-05-08 06:14:43

Dimensional Fund Advisors LP Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dimensional Fund Advisors LP grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 10.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 310,810 shares of the biotechnology company’s stock after acquiring an additional 30,615 shares during the period. Dimensional Fund Advisors LP’s holdings in Sarepta Therapeutics were worth $37,791,000 at […] - 2025-05-05 08:20:50

Mariner LLC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mariner LLC boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 14.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 8,042 shares of the biotechnology company’s stock after buying an additional 1,035 shares during the period. Mariner LLC’s holdings in Sarepta Therapeutics were worth $978,000 at the end of […] - 2025-04-28 07:59:00

Piper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target dropped by investment analysts at Piper Sandler from $182.00 to $110.00 in a report issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price target suggests a potential upside of 85.47% from the stock’s previous […] - 2025-04-23 05:10:54

Sterling Capital Management LLC Trims Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sterling Capital Management LLC lowered its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 11.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,464 shares of the biotechnology company’s stock after selling 190 shares during the period. Sterling Capital Management LLC’s holdings […] - 2025-04-22 08:13:08

Sarepta Therapeutics (NASDAQ:SRPT) Given New $182.00 Price Target at Morgan Stanley

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective decreased by Morgan Stanley from $196.00 to $182.00 in a research note published on Friday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other research analysts have also recently weighed in on SRPT. Wells Fargo & Company initiated […] - 2025-04-14 05:44:50

Schroder Investment Management Group Purchases 2,320 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Schroder Investment Management Group increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 72.4% during the fourth quarter, Holdings Channel reports. The fund owned 5,523 shares of the biotechnology company’s stock after purchasing an additional 2,320 shares during the period. Schroder Investment Management Group’s holdings in Sarepta Therapeutics were worth […] - 2025-04-08 08:16:56

LPL Financial LLC Has $6.50 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares of the biotechnology company’s stock after purchasing an additional 5,895 shares during the quarter. LPL Financial LLC’s holdings in Sarepta Therapeutics were worth $6,497,000 at the […] - 2025-04-07 07:34:54

Mitsubishi UFJ Asset Management Co. Ltd. Has $307,000 Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 11.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,429 shares of the biotechnology company’s stock after buying an additional 243 shares during the quarter. […] - 2025-04-04 08:55:06

Commonwealth Equity Services LLC Has $773,000 Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Commonwealth Equity Services LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 22.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,357 shares of the biotechnology company’s stock after purchasing an additional 1,151 shares during the period. Commonwealth Equity Services LLC’s holdings in Sarepta Therapeutics were […] - 2025-04-03 07:54:48

Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to “Sector Perform” at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $87.00 target price on the biotechnology company’s stock, down from their previous target price […] - 2025-04-02 06:00:47

Corient Private Wealth LLC Invests $786,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Corient Private Wealth LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,468 shares of the biotechnology company’s stock, valued at approximately $786,000. Several other institutional investors and […] - 2025-03-28 08:16:56

HighTower Advisors LLC Sells 2,559 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

HighTower Advisors LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 6.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,774 shares of the biotechnology company’s stock after selling 2,559 shares during the period. HighTower Advisors LLC’s holdings in Sarepta […] - 2025-03-20 09:18:48

SRPT institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	56,612	USD 975,425 -1.3%
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	32,523	USD 560,371
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	121,656	USD 2,096,133
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	49,044	USD 845,028
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	49,044	USD 845,028
2025-06-26	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,083	USD 18,660
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,036	USD 17,850
2025-06-26	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	3,872	USD 66,715
2025-06-09	IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc)	90	USD 3,574 -8.3%
Total =		314,960	USD 5,428,784

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer